BM-531 is a thromboxane A2 receptor (TXA2R) antagonist (IC50 = 7.8 nM) and thromboxane synthase inhibitor exhibiting antiplatelet activity. It inhibits arachidonic acid-induced platelet aggregation and suppresses the second wave of ADP-induced aggregation.